All Oncology News

Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.

Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

A novel risk stratification and treatment approach led to enhanced clinical outcomes overall, as well as the successful omission of radiotherapy for some patients with stage IV favorable histology Wilms tumor and pulmonary metastases.

Alexander Drilon, MD, discusses genomic drivers in non–small cell lung cancer as well as the current treatment options for patients who harbor those mutations.

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

Citing the need for additional technical information, the FDA has issued a complete response letter to Pfizer regarding a biologics license application for the trastuzumab (Herceptin) biosimilar PF-05280014.

City of Hope is currently the only institution in Southern California to offer both FDA-approved CAR T-cell therapies.

Combining ramucirumab with docetaxel in patients with locally advanced or unresectable metastatic urothelial carcinoma who progressed on platinum-based chemotherapy led to a positive trend, but not a statistically significant improvement, in overall survival.

Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.

Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.

C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.

Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.

Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer.

Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma.

Lindsay West, MD, discusses the relationship between low-fat or high-fat diets and endometrial cancer and how these can be investigated further.

Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.

The FDA has approved osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations).

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

An oncologist-led BRCA mutation testing pathway in the ENGAGE study has led researchers to conclude that pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors.

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.

Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.

The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.

Ashley A. Weiner, MD, PhD, discusses the expansions and limitations of radiotherapy in patients with non–small cell lung cancer and ongoing efforts to enhance administration and efficacy.

The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.